Delivery Order 36F79719D0170-36C24424F0066
Award Date
1/1/24
Potential Completion Date
12/31/24
Potential Value
$1.1M
Federal Agency
Veterans Integrated Service Network 4
Awardee
Progenics Pharmaceuticals Inc.
Ultimate Awardee
Lantheus Holdings, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lebanon, PA 17042, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract, valued at $505,220.80, was awarded to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and a subsidiary of Lantheus Holdings, Inc. The contract is a delivery order with a firm fixed-price pricing type, and the ultimate completion date is October...
This federal contract award is for the delivery of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract was awarded to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc., a for-profit pharmaceutical company specializing in innovative diagnostic imaging agents and targeted therapeutics for oncology. The contract, with a...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The $1,836,003.60 firm fixed price delivery order is for the procurement of PYLARIFY (piflufolastat F-18), a radiopharmaceutical used in positron emission tomography (PET) scans to detect and image prostate cancer. This contract was awarded under the Pharmaceuticals and Drugs Federal Supply...
This federal contract award, with a ceiling value of $884,136.40, was issued by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract is a delivery order issued under the Pharmaceuticals...
This federal contract award is for the delivery of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc., a prominent for-profit corporation specializing in the development, manufacturing, and distribution of diagnostic medical imaging agents and...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The $721,744 firm fixed-price delivery order is for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract is not set aside and is being issued under the...
This federal contract award is for the supply of PYLARIFY, a radiopharmaceutical product used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract, valued at $797,111.78, was awarded to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract was awarded by the Department of Veterans Affairs (VA) under a Blanket Purchase Agreement (BPA) call against the Pharmaceuticals and Drugs...
This federal contract award, valued at $855,266.64, was issued by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. The contract is for the delivery of PYLARIFY (piflufolastat F-18) injections, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract is a delivery order under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, with a...
This federal contract award is for the delivery of PYLARIFY (piflufolastat F-18), a radiopharmaceutical product used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract, valued at $230,958.08, was awarded to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is a Blanket Purchase Agreement (BPA) call under the Pharmaceuticals and Drugs Federal Supply Schedule...
This is a federal contract award to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is for the supply of the radiopharmaceutical PYLARIFY (piflufolastat F-18), a diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract is a delivery order with a firm fixed price, valued at $3,891,365.28, and has a base period plus three 1-year option years, with a total...